Close

Piper Jaffray Remains Sidelined on Trovagene (TROV) Following 2Q Miss

Go back to Piper Jaffray Remains Sidelined on Trovagene (TROV) Following 2Q Miss

Trovagene (TROV) Misses Q2 EPS by 3c

August 4, 2016 5:42 PM EDT

Trovagene (NASDAQ: TROV) reported Q2 EPS of ($0.34), $0.03 worse than the analyst estimate of ($0.31).

"I'm excited to be part of the Trovagene team," said Bill Welch, Chief Executive Officer of Trovagene. "We announced a number of significant clinical study results, publications, and new collaborations... More

Trading Radar for 8/4: Kellogg (K), MGM Resorts (MGM), Activision (ATVI), FireEye (FEYE), Weight Watchers (WTW) Report

August 3, 2016 2:51 PM EDT

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Economics:
8:30am EDT

Initial Claims - Street sees 264kContinuing Claims - no Street consensus

Earnings:

AAC Holdings (NYSE: AAC) - consensus EPS $0.23
AGCO Corp. (Nasdaq: AGCO) - consensus EPS $0.92
ANI Pharma (Nasdaq: ANIP) - consensus EPS $0.77
Acceleron Pharma (NYSE: XLRN) - consensus loss $0.50
Agios Pharma (Nasdaq:... More